<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Renal cell carcinoma prognosis &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/renal-cell-carcinoma-prognosis/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 20 Sep 2025 15:28:45 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Renal cell carcinoma prognosis &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Reticulocalbin-1: Biomarker and Therapy Target in RCC</title>
		<link>https://bioengineer.org/reticulocalbin-1-biomarker-and-therapy-target-in-rcc/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sat, 20 Sep 2025 15:28:15 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Cancer cell migration mechanisms]]></category>
		<category><![CDATA[ccRCC therapeutic targets]]></category>
		<category><![CDATA[Renal cell carcinoma prognosis]]></category>
		<category><![CDATA[Reticulocalbin-1 biomarker]]></category>
		<category><![CDATA[Tumor microenvironment modulation]]></category>
		<guid isPermaLink="false">https://bioengineer.org/reticulocalbin-1-biomarker-and-therapy-target-in-rcc/</guid>

					<description><![CDATA[Clear cell renal cell carcinoma (ccRCC) stands as the most common subtype of kidney cancer, notorious for its aggressive clinical course and poor prognosis, particularly in metastatic stages. Despite numerous advancements in cancer therapies, the quest for more effective and personalized treatment strategies for ccRCC remains a pressing challenge. In a groundbreaking study published in [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">270941</post-id>	</item>
	</channel>
</rss>
